Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E20.95 EPS (ttm)15.23 Insider Own0.10% Shs Outstand213.01M Perf Week-1.56%
Market Cap67.95B Forward P/E13.79 EPS next Y23.14 Insider Trans30.33% Shs Float210.64M Perf Month12.66%
Income3.29B PEG3.30 EPS next Q5.66 Inst Own90.90% Short Float1.56% Perf Quarter14.50%
Sales11.72B P/S5.80 EPS this Y10.30% Inst Trans0.10% Short Ratio2.45 Perf Half Y14.80%
Book/sh54.67 P/B5.84 EPS next Y7.59% ROA15.00% Target Price332.51 Perf Year12.79%
Cash/sh13.58 P/C23.49 EPS next 5Y6.36% ROE27.80% 52W Range244.28 - 330.00 Perf YTD22.13%
Dividend- P/FCF18.46 EPS past 5Y27.40% ROI21.00% 52W High-4.02% Beta0.78
Dividend %- Quick Ratio1.80 Sales past 5Y17.80% Gross Margin86.80% 52W Low29.65% ATR6.30
Employees7400 Current Ratio2.10 Sales Q/Q6.40% Oper. Margin38.70% RSI (14)58.25 Volatility1.54% 2.20%
OptionableYes Debt/Eq0.56 EPS Q/Q-15.00% Profit Margin28.10% Rel Volume0.58 Prev Close319.00
ShortableYes LT Debt/Eq0.51 EarningsOct 24 BMO Payout0.00% Avg Volume1.34M Price316.72
Recom2.10 SMA201.45% SMA506.93% SMA20014.78% Volume455,892 Change-0.71%
Sep-21-17Downgrade Raymond James Strong Buy → Mkt Perform
Sep-20-17Initiated SunTrust Buy $360
Sep-15-17Initiated RBC Capital Mkts Sector Perform $319
Jul-26-17Upgrade Goldman Neutral → Buy
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $315
Jun-19-17Upgrade UBS Sell → Neutral $262 → $270
Mar-16-17Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-16-17Downgrade Leerink Partners Outperform → Mkt Perform
Mar-02-17Initiated Instinet Buy $345
Feb-07-17Upgrade Citigroup Neutral → Buy
Dec-29-16Reiterated Raymond James Strong Buy $375 → $386
Dec-09-16Reiterated Stifel Hold $291 → $298
Nov-08-16Initiated Mizuho Buy $290
Nov-07-16Upgrade Piper Jaffray Neutral → Overweight
Nov-07-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Sep-21-17 11:09AM  Biogen: Buy or Hold? Barrons.com
09:25AM  Morning Movers: Calgon Carbon Surges, Biogen Slips, AMD Gains Barrons.com
09:06AM  Biogen's stock falls after Raymond James cuts rating by two notches MarketWatch
Sep-20-17 10:51AM  Biogen Spinoff Bioverativ Is A Buy Benzinga
08:04AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Sep-19-17 10:41AM  Profit From the Biogen Inc (BIIB) Stock Dip! InvestorPlace
07:01AM  Apple Leads 7 Top Stocks Holding In Buy Range Investor's Business Daily
Sep-18-17 11:35AM  Gilead Sciences: Is The Kite Deal Too Little, Too Late? Barrons.com
Sep-16-17 08:03AM  Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020? Motley Fool
Sep-14-17 05:01PM  Biosimilar 2017 Progress Report: Stocks in Focus Zacks
Sep-13-17 10:05AM  4 Biotech Stocks for the Long-Term InvestorPlace
Sep-12-17 08:49AM  What Is Biogen Incs (BIIB) Share Price Doing? Simply Wall St.
08:06AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
07:30AM  Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical Business Wire
Sep-11-17 10:10AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
09:33AM  Why Biogen Stock Raced Higher In August Motley Fool
08:36AM  Whats Gilead Sciences Valuation? Market Realist
Sep-08-17 10:22AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Sep-07-17 05:52PM  Despite biotech's epic run, these names are still a barga... CNBC Videos
Sep-06-17 04:01PM  Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Business Wire
Sep-01-17 07:45AM  These 4 Biotechs Just Moved Into Buy Zones; Is This Giant Next? Investor's Business Daily
07:00AM  Featured Company News - Ionis Earns Regulatory Milestone Payment from Biogen for SPINRAZA ACCESSWIRE
Aug-29-17 11:29AM  Biogen Alzheimer's Drug Shows Promise in Long-Term Study Zacks
08:03AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
07:38AM  Trade of the Day: Biogen Inc (BIIB) Stock Is Coiling InvestorPlace
07:00AM  S&P 500 Futures Fall Sharply On North Korea Launch Investor's Business Daily
Aug-28-17 04:35PM  Biogen's Alzheimer's Drug Shows Promise Could It Break Out? Investor's Business Daily
10:35AM  Head of Biogen's copycat drug unit leaves to join Scangos startup American City Business Journals
08:02AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
07:40AM  Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira(R), Approved in the European Union ACCESSWIRE
07:30AM  Biogen Reports New Data from Phase 1b Study of Investigational Alzheimers Disease Treatment Aducanumab Business Wire
Aug-27-17 08:01AM  Consider This Before You Buy Biogen Motley Fool
Aug-25-17 11:13AM  Biogen's Humira Biosimilar Imraldi Gets Approval in EU Zacks
12:00AM  Samsung, Biogen version of AbbVie's Humira approved in Europe Reuters
Aug-24-17 08:57PM  Samsung, Biogen version of AbbVie's Humira approved in Europe Reuters
07:05PM  IMRALDI®, Biogens Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union Business Wire
09:07AM  How Ioniss Spinraza Performed in 2Q17 Market Realist
Aug-23-17 06:06PM  Ionis Reports Revenue Growth in 2Q17 Market Realist
03:42PM  Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much Motley Fool
07:56AM  Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe Zacks
07:37AM  How Allergans International Segment Performed in 2Q17 Market Realist
Aug-22-17 05:29PM  ETF Topper: Biotechnology Isn't Totally on the Outs Barrons.com
09:07AM  How Allergans US Specialized Therapeutics Segment Performed in 2Q17 Market Realist
Aug-21-17 09:31AM  Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why Zacks
12:23AM  [$$] Biogen Treads Tricky Path Between Politicians, Investors The Wall Street Journal
Aug-18-17 06:24PM  [$$] Biogen Treads Tricky Path Between Politicians, Investors The Wall Street Journal
Aug-17-17 01:16PM  What's Up With Biogen? Barrons.com
08:10AM  Today's Research Reports on Stocks to Watch: Biogen Inc. and MannKind Corporation ACCESSWIRE
08:02AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Aug-16-17 02:30PM  Goldman Sachs Bet on Biogens Potential Landmark Alzheimers Drug Props Up Stock Fortune
12:40PM  Biogen gains $1B in value after Goldman Sachs touts Alzheimers drug American City Business Journals
10:51AM  Goldman has a new favorite biotech because of potential Alzheimer's blockbuster CNBC
10:46AM  Goldman has a new favorite biotech because of potential A... CNBC Videos
10:08AM  Biogen: Goldman Has Conviction! Barrons.com
10:07AM  Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List TheStreet.com
09:18AM  Goldman has a new favorite biotech because of potential Alzheimer's blockbuster CNBC
09:12AM  Goldman Sachs adds Biogen to its Americas Conviction List MarketWatch
08:02AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Aug-15-17 07:36AM  Pfizers Declining-Revenue Products in 2Q17 Market Realist
Aug-12-17 08:02AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Aug-11-17 04:07PM  Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs Motley Fool
Aug-10-17 08:04AM  IHS Markit Score downgrades Biogen Inc to 60 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
07:00AM  AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene GlobeNewswire
Aug-09-17 09:52AM  The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix Zacks
08:04AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Aug-08-17 04:33PM  Top Analyst Reports for Biogen, Activision & Cigna Zacks
04:05PM  ETFs with exposure to Biogen, Inc. : August 8, 2017 Capital Cube
Aug-07-17 09:31AM  These 3 Biotechs Just Crushed Analyst Expectations Motley Fool
Aug-03-17 04:01PM  AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa GlobeNewswire
Aug-01-17 05:48PM  Is a Beat in Store for Ionis (IONS) This Earnings Season? Zacks
12:26AM  3 ETFs to Watch Out for on Biotech Earnings Zacks
Jul-31-17 09:00AM  Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences Business Wire
Jul-28-17 10:00AM  Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies PR Newswire
09:08AM  Biogens Biosimilars Witnessed High Growth in 2Q17 Market Realist
07:40AM  Biogens Spinraza Saw High Growth in 2Q17 Market Realist
Jul-27-17 06:05PM  How Did Biogens Multiple Sclerosis Drugs Perform in 2Q17? Market Realist
04:35PM  Biogens Interferons Witnessed Steady Growth in 2Q17 Market Realist
03:00PM  How Did Biogen Perform in 2Q17? Market Realist
02:41PM  Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies PR Newswire
12:06PM  Biogen, Inc. :BIIB-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem Therapeutics Inc. ACCESSWIRE
07:10AM  Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Announces the Completion of an Immuno-Oncology Merger with Nivalis Therapeutics ACCESSWIRE
Jul-26-17 04:21PM  Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company" Motley Fool
01:48PM  Lets Hear It for Biogen Inc (BIIB) Drug Spinrazas Blockbuster Potential, Raves Cowen Top Analyst SmarterAnalyst
01:33PM  The biotech Goldman Sachs loves CNBC Videos
11:00AM  Biogen: Now That's More Like It! Barrons.com
10:09AM  19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug Benzinga
08:15AM  Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug Zacks
08:15AM  Biogen shares surge 2% after upgrade to buy at Goldman Sachs MarketWatch
Jul-25-17 10:10PM  Biogen to streamline operations and invest more in R&D American City Business Journals
09:48PM  Biogen tops Street 2Q forecasts Associated Press
08:00PM  Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records TheStreet.com
07:57PM  Edited Transcript of BIIB earnings conference call or presentation 25-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
05:08PM  Biogen Says It's Under Investigation by Milan Prosecutor Bloomberg
04:49PM  This Biotech Nearly Tripled Street Expectations For One Key Drug Investor's Business Daily
04:06PM  [$$] Biogen's Short-Term Pain To Yield Long-Term Gain Barrons.com
02:37PM  Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up Zacks
02:30PM  Biogen: Where'd My Gains Go? Barrons.com
12:55PM  Eli Lilly beats on earnings as stock dips CNBC Videos
12:35PM  Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite TheStreet.com
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 25Sale290.014,9741,442,51022,258Jul 26 04:22 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 19Sale285.007,7582,211,03027,232Jul 20 05:00 PM
Posner Brian SDirectorJun 09Sale256.311,084277,8406,330Jun 12 04:29 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,25904,027Jun 05 04:38 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,73604,663May 04 04:16 PM
Vounatsos MichelChief Executive OfficerMay 01Buy271.351,402380,4332,927May 02 04:18 PM
DENNER ALEXANDER JDirectorApr 27Buy278.5073,85820,569,476383,858May 01 05:47 PM
Clancy Paul JExecutive VP and CFOApr 25Sale290.009,8922,868,68010,813Apr 27 04:23 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratApr 03Sale274.081,981542,9527,060Apr 04 04:18 PM
Clancy Paul JExecutive VP and CFOMar 13Sale291.559,8912,883,72120,705Mar 14 07:32 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.004810718Mar 03 06:07 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratMar 01Sale290.07973282,2389,041Mar 03 06:02 PM
Clancy Paul JExecutive VP and CFOFeb 28Option Exercise0.006,780031,948Mar 02 05:24 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 28Option Exercise0.004,785010,398Mar 02 05:22 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 28Option Exercise0.005,559036,024Mar 02 05:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 28Option Exercise0.0068104,508Mar 02 05:18 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffFeb 28Option Exercise0.002,06409,237Mar 02 05:16 PM
DiPietro KennethEVP Human ResourcesFeb 28Option Exercise0.005,69608,260Mar 02 05:12 PM
Vounatsos MichelChief Executive OfficerFeb 27Buy285.391,333380,4251,434Mar 01 04:18 PM
PANGIA ROBERT WDirectorJan 09Option Exercise52.225,450284,59922,078Jan 10 04:15 PM
PANGIA ROBERT WDirectorJan 09Sale295.395,4501,609,87616,628Jan 10 04:15 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffDec 01Sale296.534814,2337,360Dec 05 04:34 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM